Intuitive Surgical vs. Boston Scientific: Which Stock Is a Better Buy Now?

Intuitive Surgical (ISRG) gained 27% in 3 months, while Boston Scientific (BSX) declined 8.6%. ISRG reported 22% revenue growth and 25% EPS increase, with strong margins. BSX saw 1.5% organic growth and EPS decline, citing cybersecurity disruptions. ISRG's growth is driven by robotic surgery adoption, while BSX faces challenges in EP and WATCHMAN. ISRG trades at a premium P/E of 36.5X, while BSX offers a discount at 11.33X. Analysts favor ISRG for its growth prospects.

Original reporting
Published Oct 30, 2026, 5:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 11:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Intuitive Surgical vs. Boston Scientific: Which Stock Is a Better Buy Now? — source image
Decision brief

The 30-second read

$ISRGBullishLow
01

Why it matters

ISRG's beat supports a bullish stance, while BSX's miss suggests caution.

02

Market read

Earnings releases for two large‑cap med‑tech stocks provide actionable signals for short‑term positioning.

03

What to watch

Potential AI integration in ISRG could face regulatory scrutiny; BSX's upcoming product launches may improve outlook later in 2027.

Relevance 4/10Novelty 4/10Timing: post‑market today

Background

The article compares Q3 earnings and outlook for Intuitive Surgical (ISRG) and Boston Scientific (BSX).

Company-level read

Ticker impact

$ISRGBullishHigh confidence
Context

Intuitive Surgical reported Q3 revenue up 22% to $3.05B and adjusted EPS $3.00, beating expectations.

Expected impact

likely upward as market prices in robust growth and margin expansion

Evidence & confidence

Quarterly beat and guidance raise provide a clear catalyst for buying pressure.

$BSXBearishHigh confidence
Context

Boston Scientific posted Q3 organic revenue growth of 1.5% and adjusted EPS of $0.73, down 3%, with a cyber‑disruption impact.

Expected impact

likely downward as investors react to earnings miss and operational issues

Evidence & confidence

Earnings miss and disclosed disruption give a clear short‑term catalyst.

Market effects

Highlights divergence in medical‑device subsectors, favoring robotic surgery over cardiovascular devices.

U.S. healthcare stocks may see rotation toward higher‑growth robotic firms.

Limited to U.S. med‑tech sector; no broader macro impact.

Counterpoint

BSX's low valuation may attract value investors despite short‑term weakness.

Key entities

  • Intuitive Surgical

    Robotic surgery equipment maker

  • Boston Scientific

    Medical device manufacturer

Related articles

$BSXMed

Blackstone Life Sciences Announces $455 Million Collaboration With Boston Scientific To Develop VITALYST Heart Pump

Blackstone Life Sciences and Boston Scientific have partnered to co-fund the development of the VITALYST heart pump, a miniature device for cardiogenic shock patients. The $455 million collaboration leverages Boston Scientific's expertise and Blackstone's investment capabilities. The VITALYST system aims to improve cardiac output and blood circulation in severe heart attack cases.

$BSXHighAI 8/10

Why Did Boston Scientific Stock Jump?

Boston Scientific (BSX) stock rose 5.6% on November 2, 2026, after announcing positive results from the SIMPLAAFY trial for its WATCHMAN heart device. The study showed that patients taking a single-drug regimen performed as well as those on two drugs, potentially simplifying post-procedure care. The company also reported a 7% decline in U.S. sales for WATCHMAN in fiscal Q3 2026.

$BSXMed

Boston Scientific and Blackstone agree on $455m VITALYST heart pump deal

Boston Scientific and Blackstone Life Sciences (BXLS) agreed to a $455m co-funding deal for the VITALYST heart pump program. The device aims to improve treatment for acute myocardial infarction cardiogenic shock. Blackstone praised Boston Scientific's cardiovascular expertise and the potential of VITALYST. Separately, Boston Scientific reported positive six-month data from the SIMPLAAFY trial for its WATCHMAN FLX Pro device.

$BXMedAI 8/10

Blackstone Life Sciences announces $455M collaboration with Boston Scientific

Blackstone Life Sciences (BX) and Boston Scientific (BSX) are collaborating on a $455M project to develop the VITALYST heart pump system. This is the first co-funding deal between the two companies. The system aims to treat acute myocardial infarction cardiogenic shock by improving blood flow. BXLS sees potential in the technology to enhance current mechanical circulatory support devices.